|1.||Wiggins, Aaron: 1 article (10/2015)|
|2.||Balasubramanian, Thangam: 1 article (10/2015)|
|3.||Ferraro, Angelo: 1 article (10/2015)|
|4.||Flanagan, R J: 1 article (01/2014)|
|5.||Handley, S A: 1 article (01/2014)|
|6.||Levkovitz, Yeciel: 1 article (04/2011)|
|7.||Tedeschini, Enrico: 1 article (04/2011)|
|8.||Papakostas, George I: 1 article (04/2011)|
|9.||Amey, C: 1 article (09/2010)|
|10.||Kennedy, Sidney H: 1 article (08/2010)|
09/01/1988 - "Compared with placebo, dothiepin produced a significant reduction in daytime pain by the end of the treatment period. "
10/01/1999 - "Dothiepin is effective in relieving pain, disability and reducing the duration of early morning stiffness in out-patients with RA. "
10/01/1999 - "Although there is a general association between pain reduction and improved anxiety and depression, the analgesic effect of dothiepin is independent of its antidepressant effect. "
10/01/1999 - "Post hoc analyses using analysis of covariance revealed that, in the dothiepin group, pain was significantly reduced by week 4 and remained so at week 12. "
09/01/1988 - "Therapy with tricyclic anti-depressants, such as dothiepin, therefore, may determine an improvement of pain indexes besides having an anti-depressant effect."
|2.||Facial Pain (Myofacial Pain)
02/11/1984 - "These results are clear evidence of the efficacy of dothiepin in psychogenic facial pain, though the drug may be needed for up to a year."
02/11/1984 - "Ninety three patients took part in a two centre double blind controlled clinical trial designed to assess the efficacy of dothiepin (Prothiaden) as compared with placebo and a soft biteguard in the treatment of psychogenic facial pain. "
01/01/1983 - "An account is given of a two-centre controlled clinical trial to assess the efficacy of dothiepin (Prothiaden) against placebo and a soft bite-guard in the treatment of psychogenic facial pain. "
|3.||Major Depressive Disorder (Major Depressive Disorders)
09/01/1997 - "Thus both treatments were effective in treating patients suffering from major depressive disorder, but patients receiving dothiepin suffered fewer adverse events and were more likely to complete their treatment."
02/01/1993 - "Of 219 elderly patients with a major depressive disorder (meeting RDC), 69 recovered sufficiently and consented to enter a two-year double-blind placebo-controlled trial of dothiepin. "
11/01/1984 - "A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder."
05/01/2005 - "To document the efficacy and tolerability of dothiepin hydrochloride in the management of major depressive disorder (MDD) in rheumatoid arthritis patients a phase IV, open, single arm, prospective study was initiated with dothiepin hydrochloride in the dose of 75 mg/day, duration of therapy was 6 weeks. "
01/01/1994 - "In a double-blind multi-centre study of general practice patients with DSM-III-R major depressive disorder, sertraline (50 or 100 mg/day) was compared with dothiepin (75 or 150 mg/day) and with placebo. "
05/01/1987 - "Dothiepin was shown to improve significantly the condition of patients with primary fibromyalgia syndrome and there was a significant difference between dothiepin and placebo in all the clinical variables measured. "
05/01/1987 - "Further controlled studies are required to define the effects of dothiepin on fibromyalgia."
05/01/1987 - "A double-blind study comparing the efficacy and tolerability of dothiepin with that of placebo in the treatment of primary fibromyalgia syndrome was carried out. "
05/01/1987 - "Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome."
|5.||Heart Diseases (Heart Disease)
10/01/1986 - "These features suggest that dothiepin may be particularly helpful for treating anxious depressed patients and patients who have underlying cardiac disease or who are elderly."
09/22/2001 - "There is good evidence for an association between dosulepin and subsequent ischaemic heart disease and for a dose-response relation."
09/22/2001 - "Increasing maximum doses of dosulepin were associated with increasing odds ratios for ischaemic heart disease. "
12/01/1986 - "We report a case of a patient on antidepressant therapy (Desipramine Hydrochloride, 50 mg/die, and Dothiepin Hydrochloride, 150 mg/die), without any underlaying heart disease, admitted to our Coronary Care Unit for recurrent syncopal episodes. "
09/22/2001 - "Patients who had ever taken dosulepin (dothiepin) had a significantly raised odds ratio for ischaemic heart disease after adjustment for confounding factors and use of other antidepressants (1.67, 1.17 to 2.36). "